Nifurtimox - Bayer
Alternative Names: Bay-2502; BAYA-2502; LampitLatest Information Update: 09 Jan 2023
At a glance
- Originator Bayer
- Class Antiprotozoals; Nitrofurans; Small molecules; Thiamorpholines; Thiazines
- Mechanism of Action DNA damage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chagas disease
- Phase II Medulloblastoma; Neuroblastoma
Most Recent Events
- 28 Oct 2022 Bayer completes a Phase-II clinical trial in Medulloblastoma (Combination therapy, In children, In adults) in USA (PO) (NCT00601003)
- 28 Oct 2022 Bayer completes a Phase-II clinical trial in Neuroblastoma (Combination therapy, In children, In adults) in USA (PO) (NCT00601003)
- 07 Aug 2020 Registered for Chagas disease (In adolescents, In children, In infants) in USA (PO)